FDA nails a third Wockhardt plant with a warning letter
The FDA sidelined U.S. biotech Cempra’s new generation antibiotic with a complete response letter last week over safety concerns, but also because of issues it has with the Wockhardt plant making the API for it.
No comments:
Post a Comment